Management of Toxicities Associated With Immune Checkpoint Inhibitors

被引:0
作者
Yun, Karen M. [1 ]
Bazhenova, Lyudmila [1 ]
机构
[1] UC San Diego Hlth, Div Hematol Oncol, Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA
关键词
Immune checkpoint inhibitors (ICIs); immune-related adverse events (irAEs); immunotherapy; ADVERSE EVENTS; REFRACTORY COLITIS; MELANOMA; PNEUMONITIS; THERAPY; PATIENT;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune-related adverse events (irAEs) encompass a diverse range of toxicities following treatment with immune check-point inhibitors (ICIs), each with distinctive symptoms, severities, and outcomes. irAEs can affect any organ and are potentially fatal, so early diagnosis is key in preventing serious events. irAEs can be fulminant, requiring immediate attention and intervention. Management of irAEs involves the use of systemic corticosteroids and immunosuppressive agents in addition to any disease-specific therapeutics. Making the decision to rechallenge with ICIs is not always clear and involves weighing the risks and clinical benefits of continuing ICI therapy. Here, we review the consensus recom-mendations on managing irAEs and discuss current challenges in clinical care caused by these toxicities.
引用
收藏
页码:142 / 149
页数:8
相关论文
共 60 条
[1]  
Abu-Sbeih H, 2021, J CLIN ONCOL, V39
[2]   Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury [J].
Abu-Sbeih, Hamzah ;
Tang, Tenglong ;
Lu, Yang ;
Thirumurthi, Selvi ;
Altan, Mehmet ;
Jazaeri, Amir A. ;
Dadu, Ramona ;
Coronel, Emmanuel ;
Wang, Yinghong .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[3]   Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study [J].
Abu-Sbeih, Hamzah ;
Ali, Faisal S. ;
Alsaadi, Dana ;
Jennings, Joseph ;
Luo, Wenyi ;
Gong, Zimu ;
Richards, David M. ;
Charabaty, Aline ;
Wang, Yinghong .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[4]  
[Anonymous], Common terminology criteria for adverse events (CTCAE)
[5]   Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events [J].
Badran, Yousef R. ;
Cohen, Justine, V ;
Brastianos, Priscilla K. ;
Parikh, Aparna R. ;
Hong, Theodore S. ;
Dougan, Michael .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
[6]   Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes [J].
Balaji, Aanika ;
Hsu, Melinda ;
Lin, Cheng Ting ;
Feliciano, Josephine ;
Marrone, Kristen ;
Brahmer, Julie R. ;
Forde, Patrick M. ;
Hann, Christine ;
Zheng, Lei ;
Lee, Valerie ;
Illei, Peter B. ;
Danoff, Sonye K. ;
Suresh, Karthik ;
Naidoo, Jarushka .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
[7]   Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis [J].
Barroso-Sousa, Romualdo ;
Barry, William T. ;
Garrido-Castro, Ana C. ;
Hodi, F. Stephen ;
Min, Le ;
Krop, Ian E. ;
Tolaney, Sara M. .
JAMA ONCOLOGY, 2018, 4 (02) :173-182
[8]   Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade [J].
Beattie, Jason ;
Rizvi, Hira ;
Fuentes, Paige ;
Luo, Jia ;
Schoenfeld, Adam ;
Lin, I-Hsin ;
Postow, Michael ;
Callahan, Margaret ;
Voss, Martin H. ;
Shah, Neil J. ;
Warner, Allison Betof ;
Chawla, Mohit ;
Hellmann, Matthew D. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
[9]   Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events [J].
Brahmer, Julie R. ;
Abu-Sbeih, Hamzah ;
Ascierto, Paolo Antonio ;
Brufsky, Jill ;
Cappelli, Laura C. ;
Cortazar, Frank B. ;
Gerber, David E. ;
Hamad, Lamya ;
Hansen, Eric ;
Johnson, Douglas B. ;
Lacouture, Mario E. ;
Masters, Gregory A. ;
Naidoo, Jarushka ;
Nanni, Michele ;
Perales, Miguel-Angel ;
Puzanov, Igor ;
Santomasso, Bianca D. ;
Shanbhag, Satish P. ;
Sharma, Rajeev ;
Skondra, Dimitra ;
Sosman, Jeffrey A. ;
Turner, Michelle ;
Ernstoff, Marc S. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
[10]   Rheumatic immune-related adverse events from cancer immunotherapy [J].
Calabrese, Leonard H. ;
Calabrese, Cassandra ;
Cappelli, Laura C. .
NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (10) :569-579